Bayer Pharma Aktiengesellschaft

The Broad Institute, Inc.

Dana-farber-cancer Institute Inc.

Bayer Aktiengesellschaft

Other

Fraunhofer-Gesellschaft Zur Foerderung Der Angewandten Forschung E.V.

Pac Tech Packaging Technologies G.m.b.h.

Bayer Pharma Aktiengessellschaft

Martin Lange

Philip Lienau

Timothy A Lewis

Heidi Greulich

Xiaoyun Wu

Ulf Bömer

Matthew Meyerson

Ulrich Bothe

Judith Günther

Holger Siebeneicher

Holger Steuber

Nicole Schmidt

Manuel Ellermann

Charlotte Christine Kopitz

Reinhard Nubbemeyer

Alex Burgin

Adrian Tersteegen

Detlev Sülzle

Christian Stegmann

Stefan Nikolaus Gradl

Peter Hauff

Alexandra Rausch

Andreas Sutter

Christian Friedrich

Ghassem Azdasht

Knut Eis

Antje Margret Wengner

Christa Hegele-Hartung

Ulrike Sack

Luc De Waal

Monica Schenone

Nicholas Charles Ray

Martina Schäfer

Andrea Rotgeri

Sven Ring

Roland Neuhaus

Horst Irlbacher

Pascal Savy

Clemens Ruthnick

Ramin Azadeh

Martina Schafer

Judith Gunther

The present invention includes name compounds of general formula (I): (I) in which R, R, Rand Rare as defined herein, methods for their preparation, pharmaceutical compositions and combinations comprising said compounds, and their use for the treatment of hyperproliferative diseases.

1,2,4-triazin-3(2H)-one compounds for the treatment of hyperproliferative diseases

The present invention provides dihydrooxydiazinone compounds of general formula (I): in which R, R, R, and R, are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of hyperproliferative diseases, as a sole agent or in combination with other active ingredients.

Dihydrooxadiazinones

The present invention features improved compounds, especially methods of identifying patients having cancer using biomarkers (e.g., PDE3A, SLFN12 and/or CREB3L1) that correlate with drug sensitivity and consequently treating a stratified patient population with an agent of the invention (e.g., Compounds 1-6 disclosed herein).

Compounds, compositions and methods for cancer patient stratification and cancer treatment

The present application relates to novel substituted indazoles, to processes for preparation thereof, to the use thereof alone or in combinations for treatment and/or prophylaxis of diseases, and to the use thereof for production of medicaments for treatment and/or prophylaxis of diseases, especially for treatment and/or prophylaxis of endometriosis and endometriosis-associated pain and other endometriosis-associated symptoms such as dysmenorrhoea, dyspareunia, dysuria and dyschezia, of lymphoma, rheumatoid arthritis, spondyloarthritis (especially psoriatic spondyloarthritis and Bekhterev's disease), lupus erythematosus, multiple sclerosis, macular degeneration, COPD, gout, fatty liver disorders, insulin resistance, neoplastic disorders and psoriasis.

Substituted indazoles, methods for the production thereof, pharmaceutical preparations that contain said substituted indazoles, and use of said substituted indazoles to produce drugs

The present invention provides dihydrooxydiazinone compounds of general formula (I) in which R, R, R, and R, are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of hyperproliferative diseases, as a sole agent or in combination with other active ingredients.

The present invention provides dihydrooxydiazinone compounds of general formula (I): in which R, R, R, and R, are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of hyperproliferative diseases, as a sole agent or in combination with other active ingredients. 

The present invention features improved compounds, especially the compound having the structure (1). Compositions and methods of identifying patients having cancer using biomarkers (e.g., PDE3A, PDE3B, SLFN12 and/or CREB3L1) that correlate with drug sensitivity and consequently treating a stratified patient population with an agent of the invention. 

Compounds, compositions and methods for cancer treatment

The present invention features improved Compounds, especially (I) methods of identifying patients having Cancer using biomarkers (e.g., PDE3A, SLFN12 and/or CREB3L1) that correlate with drug sensitivity and consequently treating a stratified patient population with an agent of the invention (e.g., Compounds 1-6 disclosed herein). 

The present invention relates to combinations of at least two components, component A and component B, component A being an inhibitor of PI3K kinase, and component B being venetoclax or palbociclib. Another aspect of the present invention relates to the use of such combinations as described herein for the preparation of a medicament for the treatment or prophylaxis of a disease, particurlarly for the treatment or prophylaxis of non-Hodgkin's lymphoma (hereinafter abbreviated to 'NHL'), particularly 1st line, 2nd line, relapsed, refractory, indolent or aggressive non-Hodgkin's lymphoma (NHL), in particular follicular lymphoma (hereinafter abbreviated to 'FL'), chronic lymphocytic leukaemia (hereinafter abbreviated to &#x201c;CLL&#x201d;), marginal zone lymphoma (hereinafter abbreviated to &#x201c;MZL&#x201d;), splenic marginal zone lymphoma (hereinafter abbreviated to &#x201c;SMZL&#x201d;), diffuse large B-cell lymphoma (hereinafter abbreviated to &#x201c;DLBCL&#x201d;), mantle cell lymphoma (MCL), transformed lymphoma (hereinafter abbreviated to &#x201c;TL&#x201d;), or peripheral T-cell lymphoma (hereinafter abbreviated to &#x201c;PTCL&#x201d;).

Combination of PI3K-inhibitors

Substituted indazoles, methods for the production thereof, pharmaceutical preparations that contain said new substituted indazoles, and use of said new substituted indazoles to produce drugs

2-substituted indazoles, methods for producing same, pharmaceutical preparations that contain same, and use of same to produce drugs

The present application relates to novel 6-substituted indazoles having a carboxamide side chain, to processes for their preparation, to their use alone or in combinations for the treatment and/or prophylaxis of diseases, and to their use for producing medicaments for the treatment and/or prophylaxis of diseases, in particular for the treatment and/or prophylaxis of endometriosis, lymphomas, macular degeneration, COPD and psoriasis.

Indazolecarboxamides, processes for their preparation, pharmaceutical preparations comprising them and their use for producing medicaments

A method of producing a contactless chip card (,) includes first the step of holding a chip (,), which is provided with terminal pads (,) on a surface thereof, in a mould defining a chip-card substrate (,), in such a way that the chip surface provided with the terminal pads is located substantially in the same plane as a chip-card substrate surface defined by the mould. In addition, a chip-card substrate material is introduced into the mould, whereupon a coil structure (,) is applied by screen-printing a conductive paste onto the chip-card substrate (,) in such a way that the coil structure (,) extends up to the terminal pads (,) on the chip.

Method for producing a contactless chip card

Growing community of inventors

Berlin, Germany

Martin Lange